2. Others
  3. Others
  4. Cf1743

Cf1743 是一种有效的抗水痘带状疱疹病毒 (VZV) 双环核苷类似物。 Cf1743 具有抗病毒活性，对 VZV 胸苷激酶 (TK) 的 IC50 为 3.3 μM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Cf1743 Chemical Structure

Cf1743 Chemical Structure

CAS No. : 319425-66-6

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Cf1743 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Cf1743 is a potent anti-varicella-zoster virus (VZV) bicyclic nucleoside analogue. Cf1743 has antiviral activity, with an IC50 of 3.3 μM for VZV thymidine kinase (TK)[1].

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
HEL EC50
> 0.5 μM
Compound: 4
Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days
Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days
[PMID: 17622128]
HEL EC50
> 1.3 μM
Compound: 4
Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days
Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days
[PMID: 17622128]
HEL EC50
> 10 μM
Compound: 4
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days
[PMID: 17622128]
HEL EC50
> 10 μM
Compound: 4
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days
[PMID: 17622128]
HEL EC50
> 20 μM
Compound: 1, BCNA
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected human HEL cells assessed as reduction in viral plaque formation after 5 days
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected human HEL cells assessed as reduction in viral plaque formation after 5 days
[PMID: 19833513]
HEL EC50
> 20 μM
Compound: 4f
Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-07 ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.
Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-07 ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.
[PMID: 11150169]
HEL CC50
> 200 μM
Compound: 4f
cytostatic concentration required to reduce the HEL cell number by 50%. after 5 days in the absence of virus
cytostatic concentration required to reduce the HEL cell number by 50%. after 5 days in the absence of virus
[PMID: 11150169]
HEL EC50
> 5 μM
Compound: 1, BCNA
Antiviral activity against TK- VZV 07 in HEL cells after 5 days
Antiviral activity against TK- VZV 07 in HEL cells after 5 days
[PMID: 18052321]
HEL EC50
> 5 μM
Compound: 1, BCNA
Antiviral activity against TK- VZV YS in HEL cells after 5 days
Antiviral activity against TK- VZV YS in HEL cells after 5 days
[PMID: 18052321]
HEL EC50
> 5 μM
Compound: 4f
Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-YS-R ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.
Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-YS-R ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.
[PMID: 11150169]
HEL CC50
> 50 μM
Compound: 4
Cytotoxicity against HEL cells after 3 days
Cytotoxicity against HEL cells after 3 days
[PMID: 17622128]
HEL EC50
0.0001 μM
Compound: 1, BCNA
Antiviral activity against TK+ VZV YS in HEL cells after 5 days
Antiviral activity against TK+ VZV YS in HEL cells after 5 days
[PMID: 18052321]
HEL EC50
0.0001 μM
Compound: 4f
Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls.
Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls.
[PMID: 11150169]
HEL EC50
0.0003 μM
Compound: 1, BCNA
Antiviral activity against TK+ VZV OKA in HEL cells after 5 days
Antiviral activity against TK+ VZV OKA in HEL cells after 5 days
[PMID: 18052321]
HEL EC50
0.0003 μM
Compound: 4f
Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls.
Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls.
[PMID: 11150169]
HEL EC50
0.0005 μM
Compound: 3
Antiviral activity against Varicella Zoster virus YS infected in HEL cells assessed as reduction in viral plaque formation after 5 days
Antiviral activity against Varicella Zoster virus YS infected in HEL cells assessed as reduction in viral plaque formation after 5 days
[PMID: 19328697]
HEL EC50
0.0006 μM
Compound: 3
Antiviral activity against Varicella Zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation after 5 days
Antiviral activity against Varicella Zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation after 5 days
[PMID: 19328697]
HEL EC50
0.001 μM
Compound: 4
Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days
Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days
[PMID: 17622128]
HEL EC50
0.004 μM
Compound: 4
Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days
Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days
[PMID: 17622128]
HEL EC50
0.0097 μM
Compound: 1, BCNA
Antiviral activity against Varicella zoster virus OKA infected human HEL cells assessed as reduction in viral plaque formation after 5 days
Antiviral activity against Varicella zoster virus OKA infected human HEL cells assessed as reduction in viral plaque formation after 5 days
[PMID: 19833513]
HeLa CC50
> 200 μM
Compound: 4
Cytotoxic concentration required to inhibit Hel cell growth by using DMSO as solvent
Cytotoxic concentration required to inhibit Hel cell growth by using DMSO as solvent
[PMID: 15993062]
分子量

398.45

Formula

C22H26N2O5
CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

Cf1743 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cf1743319425-66-6Cf 1743Cf-1743Othersvaricella-zoster virusVZVTKVZVantiviralbicyclic nucleoside analogueInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Cf1743
目录号：
HY-107025
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z